<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02125266</url>
  </required_header>
  <id_info>
    <org_study_id>V4041</org_study_id>
    <nct_id>NCT02125266</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy Study of V404 PDS in Uveitis</brief_title>
  <official_title>A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forsight Vision4</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Forsight Vision4</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the safety of V404 PDS in patients with chronic
      non-infectious uveitis. Secondarily, the study will evaluate whether V404 PDS can provide
      clinically measurable benefit over an extended period of time in patients with chronic
      non-infectious uveitis.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to unacceptable frequency of drug related adverse events
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vitreous haze score</measure>
    <time_frame>Baseline, 6 Months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in macular thickness by ocular coherence tomography</measure>
    <time_frame>Baseline, 6 Months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Uveitis, Posterior</condition>
  <condition>Uveitis, Intermediate</condition>
  <arm_group>
    <arm_group_label>Low Dose V404 PDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sustained intravitreal delivery of methotrexate (0.6 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose V404 PDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sustained intravitreal delivery of methotrexate (2.3 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V404</intervention_name>
    <description>Sustained Release</description>
    <arm_group_label>Low Dose V404 PDS</arm_group_label>
    <arm_group_label>High Dose V404 PDS</arm_group_label>
    <other_name>Methotrexate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Confirmed diagnosis of active uveitis

          -  Sufficient lens/media clarity

          -  Meet best-corrected visual acuity criteria

          -  Willing and able to use contraception

        Exclusion Criteria:

          -  Pregnant, breast feeding

          -  Uncontrolled glaucoma

          -  Intraocular surgery or periocular/intraocular injections within 6 weeks

          -  Periocular or intraocular steroid within 3 months

          -  Prior vitrectomy

          -  Prior corneal transplant

          -  Prior fluocinolone implant

          -  Allergy or sensitivity to study drug

          -  Participation in other trial within 30 days

          -  Abnormal liver function

          -  History of positive serum tuberculosis test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2014</study_first_posted>
  <disposition_first_submitted>December 7, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>December 7, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 9, 2016</disposition_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Pars Planitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

